secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001558370-24-009138
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Xilio Therapeutics expands board to nine with two new directors
---------------------------------------------------------------

- Board increased to nine directors; elected James Shannon, M.D. as Class I director (term expiring at 2025 annual meeting).
- Elected Aoife Brennan, M.D. as Class III director (term expiring at 2027 annual meeting).
- Dr. Shannon appointed to Nominating and Corporate Governance Committee; Dr. Brennan to Audit Committee.
- Both directors to receive standard non-employee director compensation and enter standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024009138/0001558370-24-009138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000155837024009138/xlo-20240613x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-009138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer